Boosters were for BA.5 variant in the US. Average percent share of BA.5 in the USA during the study period: 65%(Would be even higher if I included a lag time for infection -> hospitalization). Current percent share BA.5: 10%. Useless as a prognostic study as no new boosters are being developed to currently circulating strains.